Results

1–10 of 11 results for Diabetic Retinopathy Severity

Level of Diabetic Retinopathy Severity Correlates to Degree of Quadrant Asymmetry in Both Single and Averaged Imaged OCTA Metrics
Jesse J Jung, MD, FASRS
Annual Meeting Talks
2022
What Is the Clinical Significance of Improving Diabetic Retinopathy for Vision Outcomes? A Meta-Analysis of 5 Ranibizumab Trials
Sophie Jane Bakri, MD
Annual Meeting Talks
2021
APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies
Michael J Allingham, MD, PhD
Annual Meeting Talks
2021
Evaluation of Nonperfusion Area and Other Vascular Metrics by Widefield SS-OCTA as Biomarkers of Diabetic Retinopathy Severity
John B. Miller, MD
Annual Meeting Talks
2021
Insights Into the Progression of Diabetic Retinopathy Severity Among Primary Care Patients With Diabetes in the United States
Geeta A. Lalwani, MD
Annual Meeting Talks
2020
Patients Ultra-Responsive to Ranibizumab (RBZ): Rates of >4-Step Improvement in Diabetic Retinopathy Severity in DRCR.net Protocol S
Allen Chiang, MD, FASRS
Updates from the Field
2019
What Happens to Diabetic Retinopathy Severity Scores With Less Aggressive Treatment? A Post Hoc Analysis of the RISE and RIDE Open Label Extension Study
Roger A. Goldberg, MD, MBA
Updates from the Field
2019
Patients Ultra-Responsive to Ranibizumab (RBZ): Rates of Great Than or Equal to 4-Step Improvement in Diabetic Retinopathy Severity in DRCR.net Protocol S
Allen Chiang, MD, FASRS
Annual Meeting Talks
2019
Sustained Diabetic Retinopathy Severity Improvement With Intravitreal Aflibercept in DME: Post Hoc Analysis of VISTA and VIVID
Rishi P. Singh, MD
Annual Meeting Talks
2019
What Happens to Diabetic Retinopathy Severity Scores With Less Aggressive Treatment? A Post Hoc Analysis of the RISE and RIDE Open Label Extension Study
Roger A. Goldberg, MD, MBA
Annual Meeting Talks
2019